Gelling process differences in reverse emulsion, in situ gelling polymeric materials for intracranial aneurysm embolization, formulated with injectable contrast agents
Source abstract
Abstract
Abstract The use of liquid‐to‐solid curing materials for brain aneurysm embolization has become increasingly attractive, as liquid embolics can be delivered noninvasively and can potentially achieve a higher degree of aneurysm volume occlusion. This study was aimed at characterizing differences in the gelling process of a reverse emulsion, crosslinking polymer system formulated with different types of injectable contrast agents. The polymeric system consists of poly(propylene glycol) diacrylate (PPODA) and pentaerythritol tetrakis(3‐mercaptopropionate) (QT). These monomers undergo Michael‐type addition upon initiation by a basic, aqueous solution. Conray™ and Omnipaque™ 300, commercially available contrast agents, were pH‐adjusted to basic conditions and used as initiating solutions with the PPODA‐QT system. Material characteristics were identified through rheology and scanning electron microscopy (SEM). Results showed that Conray‐ and Omnipaque‐formulated materials progress through the gelling process uniquely, evidenced by distinctly different viscosity profiles and droplet distributions. These results indicate that Conray is more miscible with the PPODA‐QT organic phase. Greater solubility in the organic phase allows Conray‐formulated gels to have faster and more widespread reaction initiation kinetics when Conray and Omnipaque have the same pH. Omnipaque‐formulated gels require a higher pH for the material to solidify in a time frame comparable to Conray‐formulated gels. This discrepancy arises because the majority of reaction initiation sites in Omnipaque‐formulated gels occur at phase boundaries via hydroxide ion flux from emulsified droplets rather than from hydroxide ions that are solubilized and integrated within the PPODA‐QT organic phase. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2011.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Intracranial Aneurysms: Treatment and Complications · Vascular Malformations Diagnosis and Treatment · Moyamoya disease diagnosis and treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. 10.1136/jnnp.59.6.61610.1136/jnnp.59.6.616 ↗
2. 10.1161/01.STR.30.2.47010.1161/01.STR.30.2.470 ↗
3. 10.1161/01.STR.0000259824.10732.bb10.1161/01.STR.0000259824.10732.bb ↗
4. Advances in the treatment of complex cerebrovascular disorders by interventional neurovascular techniques
5. 10.3171/foc.2005.18.2.210.3171/foc.2005.18.2.2 ↗
6. Aneurysm packing with HydroCoil embolic system versus platinum coils: initial clinical experience
7. 10.1007/s00234-006-0166-010.1007/s00234-006-0166-0 ↗
8. 10.1161/01.STR.0000083394.33633.C210.1161/01.STR.0000083394.33633.C2 ↗
9. 10.1161/01.STR.0000181770.14869.ce10.1161/01.STR.0000181770.14869.ce ↗
10. 10.1227/01.neu.0000279723.67779.f010.1227/01.neu.0000279723.67779.f0 ↗
11. 10.1227/01.NEU.0000194190.45595.9E10.1227/01.NEU.0000194190.45595.9E ↗
12. Cerecyte coils in the treatment of intracranial aneurysms: A preliminary clinical study
13. 10.1161/STROKEAHA.107.48908810.1161/STROKEAHA.107.489088 ↗
14. 10.1227/01.NEU.0000255473.60505.8410.1227/01.NEU.0000255473.60505.84 ↗
15. 10.1227/01.NEU.0000143616.22174.6710.1227/01.NEU.0000143616.22174.67 ↗
16. 10.1002/jbm.1020210.1002/jbm.10202 ↗
17. 10.1097/00006123-200105000-0000310.1097/00006123-200105000-00003 ↗
18. 10.1097/00006123-199811000-0008110.1097/00006123-199811000-00081 ↗
19. Comparison of n‐butyl cyanoacrylate and ONYX for the embolization of intracranial arteriovenous malformations: analysis of fluoroscopy and procedure times
20. Onyx in treatment of large and giant cerebral aneurysms and arteriovenous malformations
21. 10.1016/S0140-6736(02)11314-610.1016/S0140-6736(02)11314-6 ↗
22. 10.1227/01.NEU.0000170538.74899.7F10.1227/01.NEU.0000170538.74899.7F ↗
23. 10.1007/s00701017007310.1007/s007010170073 ↗
24. Dense packing of cerebral aneurysms: An in vitro study with detachable platinum coils
25. 10.1007/s00234-005-1446-910.1007/s00234-005-1446-9 ↗
26. 10.1148/radiol.231303046010.1148/radiol.2313030460 ↗
27. 10.3171/jns.2002.96.3.047410.3171/jns.2002.96.3.0474 ↗
28. Cerebral aneurysm multicenter European Onyx (CAMEO) trial: Results of a prospective observational study in 20 European centers
29. 10.3171/jns.2000.93.2.017510.3171/jns.2000.93.2.0175 ↗
30. A reexamination of the angiotoxicity of superselective injection of DMSO in the swine rete embolization model
31. 10.1007/s00234-004-1323-y10.1007/s00234-004-1323-y ↗
32. 10.1227/01.NEU.0000240683.15391.9910.1227/01.NEU.0000240683.15391.99 ↗
33. 10.1097/00006123-199701000-0002610.1097/00006123-199701000-00026 ↗
34. 10.1016/j.fertnstert.2004.07.98410.1016/j.fertnstert.2004.07.984 ↗
35. 10.1002/jbm.b.3055410.1002/jbm.b.30554 ↗
36. Combined therapy of cerebral arteriovenous malformations: Histological differences between a non‐adhesive liquid embolic agent and n‐butyl 2‐cyanoacrylate (NBCA)
37. 10.1002/jbm.a.1036910.1002/jbm.a.10369 ↗
38. Targeting cerebral arteriovenous malformations for minimally invasive therapy
39. 10.1111/j.1442-2034.2004.00202.x10.1111/j.1442-2034.2004.00202.x ↗
40. Acute and chronic swine rete arteriovenous malformation models: Effect of ethiodol and glacial acetic acid on penetration, dispersion, and injection force of N‐butyl 2‐cyanoacrylate
41. Endovascular treatment of experimental aneurysms by use of a combination of liquid embolic agents and protective devices
42. A multicenter study of 705 ruptured intracranial aneurysms treated with Guglielmi detachable coils
43. 10.1227/01.NEU.0000340977.68347.5110.1227/01.NEU.0000340977.68347.51 ↗
44. “Remodelling” of the arterial wall of the parent vessel in the endovascular treatment of intracranial aneurysms (abstract)
45. Reconstruction technic in the treatment of wide‐neck intracranial aneurysms. Long‐term angiographic and clinical results. Apropos of 56 cases
46. 10.1016/j.ijpharm.2004.01.01710.1016/j.ijpharm.2004.01.017 ↗
47. 10.1002/jbm.b.3120510.1002/jbm.b.31205 ↗
48. 10.1016/j.chroma.2008.10.02110.1016/j.chroma.2008.10.021 ↗